Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Nine Months Ended December 31, 2018
Business Overview: A leading India-based pharmaceutical company operating through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Principal markets include India, the United States, Russia, and Germany.
Key Financial Metrics
Amounts in millions of Indian Rupees (Rs.) unless otherwise noted. Convenience translation to U.S. dollars provided at Rs. 69.58 = $1.00.
| Metric | 9 Months Ended Dec 31, 2018 | 9 Months Ended Dec 31, 2017 | 3 Months Ended Dec 31, 2018 | 3 Months Ended Dec 31, 2017 |
|---|---|---|---|---|
| Revenues | Rs. 113,685 ($1,634) | Rs. 106,679 | Rs. 38,500 ($553) | Rs. 38,060 |
| Gross Profit | Rs. 62,377 ($896) | Rs. 57,409 | Rs. 20,752 ($298) | Rs. 21,411 |
| Gross Margin | 54.9% | 53.8% | 53.9% | 56.3% |
| Operating Profit | Rs. 15,543 ($223) | Rs. 9,270 | Rs. 5,729 ($82) | Rs. 5,009 |
| Net Profit | Rs. 14,451 ($208) | Rs. 6,784 | Rs. 4,852 ($70) | Rs. 3,344 |
| Effective Tax Rate | 12.9% | 36.0% | 16.4% | 43.8% |
| Cash from Operations | Rs. 21,993 ($316) | Rs. 12,248 | N/A | N/A |
| Cash & Equivalents (Dec 31, 2018) | Rs. 1,712 ($25) | Rs. 2,638 (Mar 31, 2018) | ||
| Total Debt (Short + Long Term) | Rs. 43,824 ($630) | Rs. 50,621 (Mar 31, 2018) |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 7% for the nine months and 1% for the quarter compared to the prior year. Global Generics revenue grew 7% (9 months) and 4% (quarter), driven by new product launches and volume increases, partially offset by price erosion in North America. PSAI revenue grew 10% (9 months) and 9% (quarter) due to higher custom pharmaceutical services.
- Profitability Surge: Net profit for the nine months increased 113% to Rs. 14,451 million. This was primarily driven by a significant reduction in the effective tax rate (from 36.0% to 12.9%) due to the U.S. Tax Cuts and Jobs Act and favorable tax resolutions, alongside higher operating income.
- Segment Performance: Proprietary Products revenue declined 34% (9 months) and 66% (quarter) year-over-year, largely due to the absence of a one-time Rs. 1,300 million milestone payment recognized in the prior year for Impoyz™.
- Asset Disposals: The company recognized significant "Other income" from the sale of its API manufacturing business unit in Hyderabad (Rs. 423 million profit in Q4) and the sale of its Tennessee formulations facility.
- Debt Reduction: Total borrowings decreased from Rs. 50,621 million (Mar 31, 2018) to Rs. 43,824 million (Dec 31, 2018), primarily due to repayments of short-term borrowings.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Risks (FDA): The company continues to address a 2015 FDA warning letter regarding cGMP deviations at facilities in Srikakulam, Miryalaguda, and Duvvada. While the Miryalaguda API facility inspection was closed successfully in 2017, the Duvvada oncology facility and Srikakulam API facility remain under review. The FDA withheld approval of new products from these sites pending resolution. Recent re-inspections in late 2018 resulted in new observations (Form 483) that the company is addressing.
- Regulatory Risks (Germany): A German regulatory authority initially did not renew the GMP certificate for the Bachupally facility in 2017, restricting EU exports. This was resolved in January 2018. A follow-on inspection of the Duvvada facility in November 2018 concluded the facility is compliant, though one new product remains excluded.
- Legal Contingencies:
- Suboxone Litigation: Following a favorable court decision, the company launched its generic Suboxone film in June 2018. A preliminary injunction was granted by a New Jersey court but vacated by the U.S. Court of Appeals in November 2018. The company is awaiting a decision on a rehearing petition.
- Antitrust Litigation: The company is a defendant in Multi-District Litigation (MDL-2724) alleging price-fixing conspiracies involving generic drugs. The company denies wrongdoing and intends to defend vigorously.
- Patent Litigation: Ongoing proceedings regarding Namenda antitrust claims and pricing disputes with India's National Pharmaceutical Pricing Authority.
- Unusual Items:
- Tax Benefits: Significant tax expense reversal due to the U.S. tax rate reduction and resolution of prior-year tax matters.
- Investment Losses: A loss of Rs. 2,435 million was recorded in Other Comprehensive Income (OCI) due to changes in the fair value of the investment in Curis Inc.
Investor Verification Checklist
- FDA Status: Verify the current status of the FDA warning letter resolution for the Srikakulam and Duvvada facilities and any potential impact on new product approvals or existing supply chains.
- Suboxone Litigation: Monitor the outcome of the rehearing petition in the U.S. Court of Appeals regarding the Suboxone generic launch injunction.
- Antitrust Exposure: Assess the potential financial impact of the MDL-2724 price-fixing litigation, specifically regarding the drugs meprobamate, zoledronic acid, divalproex ER, and pravastatin.
- North America Pricing: Evaluate the sustainability of revenue growth in the Global Generics segment given the reported price erosion in the U.S. market.
- Investment Valuation: Review the valuation and strategic rationale for the Curis Inc. investment, which contributed significantly to OCI losses.